Shaw, Wayne

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 7,830

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials

Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Erondu, N., Shaw, W., Barrett, T. D., Weidner-Wells, M., Deng, H., Matthews, D. R., et al. (2018) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 637

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)

Mahaffey, K. W., Neal, B., Perkovic, V., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Fabbrini, E., Sun, T., Li, Q., et al. (2018) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 498

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program

Rådholm, K., Figtree, G., Perkovic, V., Solomon, S. D., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Barrett, T. D., Shaw, W., Desai, M., et al. (2018) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 488

Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes

Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Ways, K., Desai, M., Shaw, W., Capuano, G., Alba, M., et al. (2015) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 233

Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal ( CANVAS‐R ): A randomized, placebo‐controlled trial

Neal, B., Perkovic, V., Matthews, D. R., Mahaffey, K. W., Fulcher, G., Meininger, G., Erondu, N., Desai, M., Shaw, W., Vercruysse, F., et al. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 174

Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes

Li, J., Woodward, M., Perkovic, V., Figtree, G. A., Heerspink, H. J. L., Mahaffey, K. W., de Zeeuw, D., Vercruysse, F., Shaw, W., Matthews, D. R., et al. (2020) · JACC: Heart Failure

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 144

Effects of Canagliflozin on Amino-Terminal Pro–B-Type Natriuretic Peptide

Januzzi, J. L., Xu, J., Li, J., Shaw, W., Oh, R., Pfeifer, M., Butler, J., Sattar, N., Mahaffey, K. W., Neal, B., et al. (2020) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 97

Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: A pooled analysis

Sinclair, A. J., Bode, B., Harris, S., Vijapurkar, U., Shaw, W., Desai, M., & Meininger, G. (2016) · Journal of the American Geriatrics Society

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 87

Canagliflozin and Stroke in Type 2 Diabetes Mellitus: Results From the Randomized CANVAS Program Trials

Zhou, Z., Lindley, R. I., Rådholm, K., Jenkins, B., Watson, J., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Shaw, W., et al. (2019) · Stroke

Diabetes Treatment and ManagementAcute Ischemic Stroke Management

Cited by 72

Efficacy and safety of canagliflozin used in conjunction with sulfonylurea in patients with type 2 diabetes mellitus: a randomized, controlled trial

Fulcher, G., Matthews, D. R., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Weiss, R., Rosenstock, J., Capuano, G., Desai, M., Shaw, W., et al. (2015) · Diabetes Therapy

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 44